C7287
Canrenoic acid potassium salt
powder
Synonym(s):
17-Hydroxy-3-oxopregna-4,6-diene-21-carboxylic acid, Potassium canrenoate
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Linear Formula:
C22H30O4K
CAS Number:
Molecular Weight:
397.57
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352106
EC Number:
218-554-9
MDL number:
InChI key
YLXFIHIYNGPPSF-HUHWECDNSA-N
InChI
1S/C22H30O4.K.H/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25;;/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25);;/t16-,17+,18+,20+,21+,22-;;/m1../s1
SMILES string
[K].[H][C@]12CC[C@@]3(C)[C@@]([H])(CC[C@@]3(O)CCC(O)=O)[C@]1([H])C=CC4=CC(=O)CC[C@]24C
form
powder
color
light yellow to tan
Quality Level
Application
Canrenoic acid potassium salt has been used as a human uridine 5′-diphospho (UDP)-glucuronosyltransferase inhibitor to study its effects on trifluoperazine (TFP) substrate selectivity. It has also been used to study its effects on the formation of aldosterone 18-glucuronide (ALDO 18β-G) in recombinant UDP-Glucuronosyltransferase-2B7 (UGT2B7), human liver (HLM) and human kidney cortical (HKCM) microsomes.
Biochem/physiol Actions
Competitive aldosterone receptor antagonist.
Competitive aldosterone receptor antagonist. Potassium canrenoate reduces the effects of aldosterone-induced increases in blood pressure and in cardiovascular fibrosis in animals with high sodium intake. It is used clinically for its anti-fibrotic effects. At higher doses it is genotoxic to liver and increases tumor incidence in rodent models.
Analysis Note
Aqueous solutions may contain some insoluble material.
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Rita Berardelli et al.
European journal of endocrinology, 162(6), 1067-1074 (2010-03-12)
Mineralocorticoid receptors (MRs) in the hippocampus display an important role in the control of the hypothalamic-pituitary-adrenal (HPA) axis, mediating the proactive feedback of glucocorticoids, which maintains the basal HPA activity. The systemic administration of MR antagonists enhances spontaneous and CRH-stimulated
Helen C Atkinson et al.
American journal of physiology. Endocrinology and metabolism, 294(6), E1011-E1022 (2008-03-20)
The aim of this study was to investigate fast corticosteroid feedback of the hypothalamic-pituitary-adrenal (HPA) axis under basal conditions, in particular the role of the mineralocorticoid receptor. Blood samples were collected every 5 min from conscious rats at the diurnal
Wenxia Chai et al.
Journal of hypertension, 28(5), 1044-1053 (2010-02-25)
To test whether glucocorticoids act as the endogenous agonist of cardiac mineralocorticoid receptors, we evaluated the cardiac effects of aldosterone and corticosterone and cardiac steroidogenesis vs. steroid uptake from plasma. Both corticosterone and aldosterone increased left ventricular pressure in the
Monica Minnaard-Huiban et al.
Endocrinology, 149(1), 28-31 (2007-09-22)
Reversal of cardiac fibrosis is a major determinant of the salutary effects of mineralocorticoid receptor antagonists in heart failure. Recently, R-fadrozole was coined as an aldosterone biosynthesis inhibitor, offering an appealing alternative to mineralocorticoid receptor antagonists to block aldosterone action.
Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone)?probes? for human UDP-glucuronosyltransferases
Uchaipichat V, et al.
Drug Metabolism and Disposition, 34(3), 449-456 (2006)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service